Metraipolis › archive › dc_3764e3458efd

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer — Europe PMC PMID:41335461

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41335461
DOI
10.1093/oncolo/oyaf400
License (as archived)
solo-consultazione
Archived
2026-11-08T03:28:56.720Z
SHA-256 of the archived text
966578dd85fbefe5765a526d31be907c02356ab7647857532ebd5a8ffe16c3e4
Stable URL of this page
https://metraipolis.com/documento/dc_3764e3458efd

How to cite

NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer — Europe PMC PMID:41335461 — Europe PMC (en), https://europepmc.org/article/MED/41335461 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_3764e3458efd (Metraipolis archive dc_3764e3458efd, sha256 966578dd85fbefe5765a526d31be907c02356ab7647857532ebd5a8ffe16c3e4)
BibTeX
@misc{dc3764e3458efd,
  title = {NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer — Europe PMC PMID:41335461},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41335461},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_3764e3458efd; sha256 966578dd85fbefe5765a526d31be907c02356ab7647857532ebd5a8ffe16c3e4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41335461. Agents can read the archived copy with the MCP tool read_document.